Title:
NUCLEIC ACID DRUG TARGETING EBV-RELATED DISORDERS
Document Type and Number:
WIPO Patent Application WO/2023/127848
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a novel nucleic acid molecule capable of simultaneously suppressing multiple miR-BART. Provided is a nucleic acid molecule comprising a base sequence complementary to at least a portion of the primary transcript of the BART region of Epstein-Barr virus (EBV) genome, and having an antisense effect on multiple target miRNA.
Inventors:
ARAI AYAKO (JP)
YOKOTA TAKANORI (JP)
YOSHIOKA KOTARO (JP)
YOSHIMORI MAYUMI (JP)
SHIMIZU NORIO (JP)
YOKOTA TAKANORI (JP)
YOSHIOKA KOTARO (JP)
YOSHIMORI MAYUMI (JP)
SHIMIZU NORIO (JP)
Application Number:
PCT/JP2022/048097
Publication Date:
July 06, 2023
Filing Date:
December 27, 2022
Export Citation:
Assignee:
UNIV NAT CORP TOKYO MEDICAL & DENTAL (JP)
International Classes:
C12N15/113; A61K31/7105; A61K31/7115; A61K31/7125; A61K31/713; A61K47/54; A61K48/00; A61P25/00; A61P31/22; A61P35/00
Domestic Patent References:
| WO2017068790A1 | 2017-04-27 |
Foreign References:
| JP2019038755A | 2019-03-14 |
Other References:
K A LENNOX, M A BEHLKE: "Chemical modification and design of anti-miRNA oligonucleotides", GENE THERAPY, MACMILLAN PRESS LTD., vol. 18, no. 12, 14 December 2011 (2011-12-14), pages 1111 - 1120, XP055156922, ISSN: 09697128, DOI: 10.1038/gt.2011.100
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF:
Previous Patent: BEVERAGE CONTAINING STEVIOL GLYCOSIDE
Next Patent: STRUCTURE FOR COMPOUND SCAVENGING
Next Patent: STRUCTURE FOR COMPOUND SCAVENGING